Immediate Impact

64 standout
Sub-graph 1 of 22

Citing Papers

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2023 Standout
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
2023 Standout
1 intermediate paper

Works of Manuel Figueroa being referenced

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists
2005

Author Peers

Author Last Decade Papers Cites
Manuel Figueroa 510 612 1002 54 1.9k
Shigeko Inokuma 339 550 1245 76 2.3k
Vicente Rodríguez‐Valverde 413 1128 1981 66 3.1k
Peter T. Chapman 746 324 1227 82 3.1k
César Hernández‐García 206 743 1152 39 1.8k
Évangéline Pillebout 382 944 492 61 2.4k
Allan L. Metzger 606 355 1402 49 2.9k
Michael Seitz 144 639 984 62 2.4k
Andrew Exley 349 1165 585 44 2.3k
Carine Salliot 283 136 1446 62 2.4k
J. Dixey 227 569 1739 48 2.6k

All Works

Loading papers...

Rankless by CCL
2026